Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Foster

Showing results (1151-1160 of 1,472) with videos related to

Pageof 148
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 22, 2004
Gemcitabine and ISIS-2503 for patients with locally advanced or metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II trialSteven R Alberts, Mark Schroeder, Charles Erlichman, et al.
British Journal of Cancer|May 12, 2005
Plucked human hair as a tissue in which to assess pharmacodynamic end points during drug development studiesD R Camidge, K R Randall, J R Foster, et al.
Canadian Journal of Anaesthesia = Journal Canadien D'Anesthesie|March 20, 2024
Impact of COVID-19-related restricted family presence policies on Canadian pediatric intensive care unit clinicians: a qualitative studyMolly J Ryan, Laurie Lee, Sara Drisdelle, et al.
The Oncologist|January 26, 2019
A Phase II Randomized Trial of Panitumumab, Erlotinib, and Gemcitabine Versus Erlotinib and Gemcitabine in Patients with Untreated, Metastatic Pancreatic Adenocarcinoma: North Central Cancer Treatment Group Trial N064B (Alliance)Thorvardur R Halfdanarson, Nathan R Foster, George P Kim, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|August 15, 2014
Matrix metalloproteinase 9-mediated shedding of syndecan 4 in response to tumor necrosis factor α: a contributor to endothelial cell glycocalyx dysfunctionRaina Ramnath, Rebecca R Foster, Yan Qiu, et al.
Journal of Hepatology|June 25, 2017
Safety of the 2D/3D direct-acting antiviral regimen in HCV-induced Child-Pugh A cirrhosis - A pooled analysisFred Poordad, David R Nelson, Jordan J Feld, et al.
Insects|April 30, 2021
Nootkatone Is an Effective Repellent against <i>Aedes aegypti</i> and <i>Aedes albopictus</i>Taylor C Clarkson, Ashley J Janich, Irma Sanchez-Vargas, et al.
Journal of Viral Hepatitis|February 6, 2023
The tolerability of sofosbuvir/velpatasvir for 12 weeks in patients treated in the ASTRAL 1, 2 and 3 studies: A pooled safety analysisIra M Jacobson, Stefan Bourgeois, Phillipe Mathurin, et al.
Immunology|May 1, 2008
Widespread natural variation in murine natural killer T-cell number and functionStacia L Rymarchyk, Hayden Lowenstein, Jana Mayette, et al.
Alimentary Pharmacology & Therapeutics|June 1, 2019
The association between hepatocellular carcinoma and direct-acting anti-viral treatment in patients with decompensated cirrhosisAli Jibran Mecci, Polychronis Kemos, Clifford Leen, et al.
Pageof 148

Showing results (1151-1160 of 1,472) with videos related to

Sort By:
Pageof 148
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 22, 2004
Gemcitabine and ISIS-2503 for patients with locally advanced or metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II trialSteven R Alberts, Mark Schroeder, Charles Erlichman, et al.
British Journal of Cancer|May 12, 2005
Plucked human hair as a tissue in which to assess pharmacodynamic end points during drug development studiesD R Camidge, K R Randall, J R Foster, et al.
Canadian Journal of Anaesthesia = Journal Canadien D'Anesthesie|March 20, 2024
Impact of COVID-19-related restricted family presence policies on Canadian pediatric intensive care unit clinicians: a qualitative studyMolly J Ryan, Laurie Lee, Sara Drisdelle, et al.
The Oncologist|January 26, 2019
A Phase II Randomized Trial of Panitumumab, Erlotinib, and Gemcitabine Versus Erlotinib and Gemcitabine in Patients with Untreated, Metastatic Pancreatic Adenocarcinoma: North Central Cancer Treatment Group Trial N064B (Alliance)Thorvardur R Halfdanarson, Nathan R Foster, George P Kim, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|August 15, 2014
Matrix metalloproteinase 9-mediated shedding of syndecan 4 in response to tumor necrosis factor α: a contributor to endothelial cell glycocalyx dysfunctionRaina Ramnath, Rebecca R Foster, Yan Qiu, et al.
Journal of Hepatology|June 25, 2017
Safety of the 2D/3D direct-acting antiviral regimen in HCV-induced Child-Pugh A cirrhosis - A pooled analysisFred Poordad, David R Nelson, Jordan J Feld, et al.
Insects|April 30, 2021
Nootkatone Is an Effective Repellent against <i>Aedes aegypti</i> and <i>Aedes albopictus</i>Taylor C Clarkson, Ashley J Janich, Irma Sanchez-Vargas, et al.
Journal of Viral Hepatitis|February 6, 2023
The tolerability of sofosbuvir/velpatasvir for 12 weeks in patients treated in the ASTRAL 1, 2 and 3 studies: A pooled safety analysisIra M Jacobson, Stefan Bourgeois, Phillipe Mathurin, et al.
Immunology|May 1, 2008
Widespread natural variation in murine natural killer T-cell number and functionStacia L Rymarchyk, Hayden Lowenstein, Jana Mayette, et al.
Alimentary Pharmacology & Therapeutics|June 1, 2019
The association between hepatocellular carcinoma and direct-acting anti-viral treatment in patients with decompensated cirrhosisAli Jibran Mecci, Polychronis Kemos, Clifford Leen, et al.
Pageof 148